The Antibody Lab

The Antibody Lab GmbH is a private biotechnology company based in Vienna, Austria. According to its official website, the company leverages antibody engineering and protein expression know-how to develop immunoassays and preclinical biologics for its partners and customers. It is financed by its founders and by a revenue stream from existing partnerships with various life science companies, and some of its R&D projects are supported by grants from Austrian public agencies (FFG, Wirtschaftsagentur Wien, aws) and European public agencies. The company operates from Divischgasse 4 in Vienna's 21st district, and its legal notice lists Renate Berger-Mostler as Managing Director. It is registered in the Austrian commercial register (Handelsgericht Wien) under FN 325059d and VAT number ATU 64831757. The company has been active in the Vienna life-science ecosystem, including establishing a cell line development laboratory at the Vienna Biocenter (VBC3) in 2018. The Antibody Lab's offering spans antibody production services, proprietary cell expression technology, and assay development. It introduced an Antibody Production Service in 2018 and has offered its BESTcell mammalian cell expression system to customers needing high-producing cell lines. Its development activities have included a proprietary point-of-care assay to diagnose sepsis in companion animals, pursued with the Veterinary Diagnostics Institute (VDxI) in the USA, and a collaboration with Angothera on Animal Health vaccines. The company has been featured in Biopharma Dealmakers, a partnering supplement to Nature Biotechnology, Nature Medicine and Nature Reviews Drug Discovery, in 2016 and 2018. It has also made strategic decisions about its technology portfolio, such as terminating its license for BAC-based cell line development in 2020. As a privately held company financed by founders and partnerships, it does not appear on public stock exchanges.

The Antibody Lab GmbH is a private biotechnology company headquartered in Vienna, Austria. Its official website describes it as leveraging antibody engineering and protein expression know-how to develop immunoassays and preclinical biologics for partners and customers. The company is financed by its founders and by revenue from existing partnerships with various life science companies, and some of its R&D projects are supported by grants from Austrian public agencies (FFG, Wirtschaftsagentur Wien, aws) and European public agencies. A significant early milestone came in April 2016, when The Antibody Lab began offering its proprietary BESTcell mammalian cell expression system to customers in need of high-producing cell lines. In May 2016 the company was covered in the June 2016 edition of Biopharma Dealmakers, a partnering supplement to Nature Biotechnology, Nature Medicine and Nature Reviews Drug Discovery. In August 2016, The Antibody Lab agreed with the Veterinary Diagnostics Institute (VDxI) in the USA on further development of its proprietary point-of-care assay to diagnose sepsis in companion animals; under the agreement, VDxI would be responsible for clinical development and marketing in North America. In April 2017, The Antibody Lab and Angothera agreed to collaborate on the development of Animal Health vaccines. In January 2018, the company started its new cell line development laboratory at the Vienna Biocenter (VBC3), strengthening its infrastructure in Vienna's life-science cluster. In March 2018, it introduced its new Antibody Production Service. In September 2018, the company was again covered in Biopharma Dealmakers, this time in the September 2018 edition. In March 2020, The Antibody Lab announced it was terminating its license for BAC-based cell line development, a strategic decision reflecting a shift in its technology portfolio. The company's legal notice lists its address as Divischgasse 4, A-1210 Vienna, Austria, with Renate Berger-Mostler as Managing Director. It is registered in the Austrian commercial register under FN 325059d (Handelsgericht Wien) and VAT number ATU 64831757. As a privately held company financed by founders and partnerships, it does not appear on public stock exchanges.

• The Antibody Lab offers its proprietary BESTcell mammalian cell expression system to customers in need of high producing cell lines.

• The Antibody Lab is covered in the June 2016 edition of Biopharma Dealmakers.

• The Antibody Lab agrees with Veterinary Diagnostics Institute (VDxI), USA, on further development of its proprietary point-of-care assay to diagnose sepsis in companion animals.

• The Antibody Lab and Angothera agree to collaborate on the development of Animal Health vaccines.

• The Antibody Lab starts its new cell line development lab at the Vienna Biocenter, VBC3.

• The Antibody Lab introduces its new Antibody Production Service.

• The Antibody Lab is covered in the September 2018 edition of Biopharma Dealmakers.

• The Antibody Lab terminates its license for BAC-based cell line development.

Private biotechnology company offering antibody engineering, protein expression, immunoassay and preclinical biologics development services to partners and customers.

• Antibody Production Service

  Service introduced in March 2018 for antibody production.

• BESTcell mammalian cell expression system

  Proprietary expression system offered to customers in need of high producing cell lines.

• Point-of-care assay for sepsis in companion animals

  Proprietary assay under development with Veterinary Diagnostics Institute (VDxI) for North American clinical development and marketing.

1. 1The Antibody Lab - The Antibody Labtheantibodylab.com
2. 2Legal Notice / Impressum - The Antibody Labtheantibodylab.com
3. 3The Antibody Lab GmbHwikidata.org